Company: CMND
Filing Date: 2025-12-05
Form Type: F-1/A
Source: 0001213900-25-118772
Chunk: 11

Company: Clearmind Medicine Inc.
Filing Date: 2025-12-05
Form: F-1/A
Chunk 11
---
 their contractual terms which precluded equity classification, that were issued in our financings in April 2023 and January 2024 for aggregate gross proceeds of approximately $183,000 (see “Recent Developments—Warrant Exercises” below for additional information). We expect that we will be able to demonstrate compliance with the Nasdaq stockholders’ equity requirement as a result of such financing and warrant exercises.

8 November 2025 Registered Direct Offerings On November 13, 2025, we entered into a securities purchase agreement with investors for the purchase and sale of (i) 958,222 common shares, and (ii) pre-funded warrants to purchase up to 2,984,146 common shares, in a registered direct offering, or the First November 2025 Offering, at a purchase price of $0.20 per common share and $0.1999 per pre-funded warrant. The pre-funded warrants are immediately exercisable at an exercise price of $0.0001 per common share, subject to adjustment as set forth therein, and will not expire until exercised in full. The November 2025 Offering closed November 13, 2025. The aggregate gross proceeds to the Company were approximately $0.788 million. On November 17, 2025, we entered into a securities purchase agreement with investors for the purchase and sale of (i) 3,991,768 common shares, and (ii) pre-funded warrants to purchase up to 1,518,000 common shares, in a registered direct offering, or the Second November 2025 Offering, at a purchase price of $0.25 per common share and $0.2499 per pre-funded warrant. The pre-funded warrants are immediately exercisable at an exercise price of $0.0001 per common share, subject to adjustment as set forth therein, and will not expire until exercised in full. The Second November 2025 Offering closed November 17, 2025. The aggregate gross proceeds to the Company were approximately $1.377 million. On November 19, 2025, we entered into a securities purchase agreement with investors for the purchase and sale of 10,925,000 common shares in a registered direct offering, or the Third November 2025 Offering, at a purchase price of $0.20 per common share. The Third November 2025 Offering closed November 20, 2025. The aggregate gross proceeds to the Company were approximately $2.185 million. On November 26,